AXT's permit-backed Q4 outlook weakens the near-term operating objection to the Sell case. Q3 revenue reached $73.4M at 56% GAAP gross margin; management guides to about $90M in Q4 from business permitted or not needing permits. InP contributed $54.3M and backlog exceeds $500M, though much spans years. The remaining test is whether 2027 capacity becomes qualified, permitted shipments at durable margins. x.com  x.com  x.com 

AXT's indium phosphide business is at China's mercy, since its expansion inside China lets Beijing decide every line item on every purchase order. Per a report shared by @wallstengine, US officials are pressing China over delayed InP export approvals as the material becomes an AI data center bottleneck, and AXT says export permits are its biggest challenge. The stock was rejected at resistance despite that news. x.com  x.com  x.com 

AXT is a speculative add on the market's sharp drop, because indium phosphide wafer prices have reportedly risen a lot lately. x.com 

AXT cannot be the dominant indium phosphide substrate supplier when its customers' supply depends on the Chinese government's export permitting. Lumentum has locked up InP supply for several years with Sumitomo, a larger competitor that does not face the same export restrictions. Doubling down on manufacturing in China is an odd choice given continuous permitting roadblocks. Substrate pricing is unlikely to go parabolic, despite Serenity's claims of 10x+ price increases. x.com  x.com 

AXT looks like a shell of Chinese companies at an absurd valuation: about 30x next year's sales and likely over 100x 2027 gross profit for a low-margin commodity business. Its manufacturing and most operations are in mainland China, while its US auditor has no China operations. The stock is up about 67% from last week's secondary pricing, and its only 5%+ holder has filed on just one other stock, a penny stock. x.com  x.com 

AXT's indium phosphide substrate chokepoint gives it pricing potential, though its Coherent agreement caps annual wafer-price increases. Channel checks suggest increases of 50-60% in Q2 2026, 10% in Q3 and over 10% in Q4. With supply agreements to Lumentum and Coherent, AXT probably becomes No. 1 ahead of Sumitomo Electric. A SanDisk-style hike now looks less likely because of the annual cap, whose percentage is redacted. x.com 

AXT is a stock nobody should own because of its China risk, but it is not a long-term short. It sits at a major choke point with 40% market share in InP lasers, so unless China turns the lights off, the stock can still rally to higher extremes; gains from shorting it this week are worth taking. x.com 

AXT priced its secondary offering a steep 22.5% below the prior close, another sign the company is less legitimate than its choke-point story suggests. It follows the appointment of a CFO who had served a five-year officer ban. x.com 

AXT is the upstream chokepoint of the photonics buildout, supplying the indium phosphide substrates every high-speed laser needs amid a massive global shortage. About 600,000-700,000 wafers shipped in 2025 against demand of 1.5-2 million, and AXT holds roughly 36% of a market three firms control. Record revenue rose 164% to $47.6M and gross margin hit 45% from 8.2%; Lumentum prepaid $87M to reserve capacity through 2031. The real risk is China, where slow export permits caused a guidance miss. … Show more

AXT looks very bearish on the risk that China stops allowing indium phosphide exports to the US. The same export question raises doubt over whether US companies will even be able to use CXMT DRAM. x.com